What Happened?
South San Francisco, CA-based Annexon Biosciences Appointed Doug Love as Chief Executive Officer
Date of management change: December 15, 2014
South San Francisco, CA-based Annexon Biosciences Appointed Doug Love as Chief Executive Officer
Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.
Doug Love is Chief Executive Officer at Annexon Biosciences. Previously, Doug held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Woolsey Roger, Jones Courtney, Wicker Craig, Lloyd Ron, Chambliss Angela, Samuels Lawrence, Lenz James, Ely Debra, Peabody Mark, Hampton Amanda, Murphy Michael
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.